Stay updated on Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe page adds a reference to Hepatocellular carcinoma and includes the Genetic and Rare Diseases Information Center as a resource. It also updates the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page revision was updated from v3.4.0 to v3.4.1; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous v3.3.3. This appears to be a minor version update to the page template.SummaryDifference0.0%

- Check104 days agoChange DetectedThe page's Locations list was updated with numerous additions and deletions across the United States, Canada, Europe, Australia, and Asia. This changes the study's geographic footprint and which sites are available to potential participants.SummaryDifference3%

Stay in the know with updates to Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in HCC After Sorafenib Clinical Trial page.